2022 Annual Convention - Day 3

Lunch Symposium 1 (Boehringer Ingelheim)

Prof. Richard O’Brien : The GEM of T2D Management: Addressing Glycemia and CRM Goals in T2D thru SGLT2 inhibitor and DPP4 inhibitor Drug Combination

 

Lunch Symposium 2 (Servier)

Bien Matawaran, MD : Highly-Advanced Metabolic Approach as Optimal Solution to Improve Angina Management

 

Lunch Symposium 3 (Novo Nordisk)

Prof. Frederik Persson and Peter Rossing : Better Outcomes with Once-Weekly Semaglutide in T2D

 

Lunch Symposium 4 (Astra Zeneca)

Ariel Miranda, MD : Heart Failure: The Next Chapter

 

Plenary 7

Susan Samson, MD : Cyclical Cushing’s Syndrome: A Vicious Cycle of Hypercortisolism

 

Plenary 8

Maria Cabanillas, MD : Personalized Therapy for Advanced Thyroid Cancer

 

Concurrent Symposium 1: Endocrine Effects among Special Populations

Lizette Lopez, MD: Long-Term Risk of Cross-Sex Hormone Therapy

Maria Luisa Patricia Gatbonton, MD: Updates in Long-Term Maternal and Fetal Adverse Effects of Gestational Diabetes Mellitus

Aimee Andag-Silva, MD: Long-Term Endocrine and Metabolic Consequences of Cancer Treatment

Mary Henry Joven, MD: Endocrine Frailty in the Elderly

 

Concurrent Symposium 2: PCOS: Modern Medical Quandry

Elizabeth Paz-Pacheco, MD: Diabetes: Metabolic and Reproductive Disorders in Women

Bien Matawaran, MD: Clinical Impact of Insulin Resistance in Women with PCOS

Gladys Tanangonan, MD: Gynecologic Updates in the Management of PCOS

Lovie Hope Go-Chu, MD: Psychological Burden among Women with PCOS

 

Closing Remarks